SCHEMBL21311225

SCHEMBL21311225

Nc1ncnc2c1ncn2C1OC(CNCn2cnc3c(CCc4ccco4)ncnc32)C(O)C1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DOT1L Q8TEK3 3/20 0.54
▸ ATM Q13315 1/20 0.54
▸ ADORA3 P0DMS8 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ SLC29A1 Q99808 2/20 0.52
▸ DPP4 P27487 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ SLC28A1 O00337 1/20 0.52
▸ MAP3K7 O43318 1/20 0.52
▸ SLC28A2 O43868 1/20 0.52
▸ GAPDH P04406 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ ADORA2A P29274 1/20 0.52
▸ ADORA2B P29275 1/20 0.52
▸ ADORA1 P30542 1/20 0.52
▸ STAT6 P42226 1/20 0.52
▸ PI4KA P42356 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ PI4K2B Q8TCG2 1/20 0.52
▸ PI4K2A Q9BTU6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20097018 0.87 ADORA3 (0.70) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL21311165 0.86 DOT1L (0.69) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL21311166 0.81 DOT1L (0.61) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL20097005 0.80 ATM (0.61) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL20097009 0.79 ATM (0.60) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL21311357 0.78 DOT1L (0.59) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL20097011 0.77 ATM (0.60) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL20096943 0.77 DOT1L (0.66) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL20097019 0.76 DOT1L (0.57) DOT1LATMADORA3SMN1; SMN2SLC29A1
SCHEMBL6907808 0.76 DOT1L (0.69) DOT1LDPP4NADKAHCY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS POLRMT, EIF2AK2, NSUN3 DOT1L 2274/4885ATM 3776/4885ADORA3 2754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback